Vascular endothelial growth factor pathway

Pharmacogenetics and Genomics

Volumn 20, Issue 5, 2010, Pages 346-349

  Maitland, Michael L ^a   Lou, Xing Jian ^c   Ramirez, Jacqueline ^a   Desai, Apurva A ^a   Berlin, Dorit S ^c   McLeod, Howard L ^b   Weichselbaum, Ralph R ^a   Ratain, Mark J ^a   Altman, Russ B ^c   Klein, Teri E ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; BRIVANIB; CILENGITIDE; MOTESANIB; PACLITAXEL; SORAFENIB; SUNITINIB; VANDETANIB; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CLINICAL TRIAL; GENETIC VARIABILITY; GENOTYPE; HUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PHARMACOGENETICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77951490529     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283364ed7     Document Type: Short Survey

References (22)

1. Fujita Y, Abe R, Shimizu H. Clinical approaches toward tumor angiogenesis: past, present and future. Curr Pharm Des 2008; 14:3820-3834.
2. Tonra JR, Hicklin DJ. Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. Immunol Invest 2007; 36:3-23. (Pubitemid 46024914)
3. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64:7099-7109. (Pubitemid 39331023)
4. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9:327-337. (Pubitemid 36109749)
5. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole- 3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46:1116-1119. (Pubitemid 36428215)
6. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, et al. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5- yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-yl)2- aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 51:1976-1980. (Pubitemid 351438880)
7. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008; 14:6146-6153.
8. Goodman SL, Holzemann G, Sulyok GA, Kessler H. Nanomolar small molecule inhibitors for alphav (beta)6, alphav (beta)5, and alphav (beta)3 integrins. J Med Chem 2002; 45:1045-1051.
9. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-5483. (Pubitemid 46300140)
10. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66:8715-8721. (Pubitemid 44449188)
11. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62:4645-4655.
12. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26:4672-4678.
13. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2008; 111:157-163. (Pubitemid 352009224)
14. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q, et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65:5015-5019. (Pubitemid 40827307)
15. Garcia-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D, et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007; 3:e29. (Pubitemid 46318407)
16. Clar H, Krippl P, Renner W, Langsenlehner T, Clar V, Windhager R, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2009; 113:197-198.
17. Langsenlehner U, Wolf G, Langsenlehner T, Gerger A, Hofmann G, Clar H, et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian 'tumor of breast tissue: incidence, genetics, and environmental risk factors' Study. Breast Cancer Res Treat 2008; 109:297-304. (Pubitemid 351644853)
18. Jacobs EJ, Feigelson HS, Bain EB, Brady KA, Rodriguez C, Stevens VL, et al. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res 2006; 8:R22. (Pubitemid 44377909)
19. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 2005; 11:3647-3653. (Pubitemid 40685580)
20. Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, Clar H, et al. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol 2008; 134:591-595. (Pubitemid 351422611)
21. Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, et al. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer 2008; 44:1572-1576. (Pubitemid 351422611)
22. Zhai R, Liu G, Zhou W, Su L, Heist RS, Lynch TJ, et al. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res 2008; 14:612-617. (Pubitemid 351226132)